Pulmonx Corporation (LUNG) Stock

Pulmonx Corporation (LUNG) is a Healthcare stock trading at $2.31 (as of 2026-08-20), with a market capitalization of $97.57M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Understand Pulmonx Corporation: how it makes money

Pulmonx makes minimally invasive respiratory medical technology for chronic obstructive pulmonary disease, including the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the StratX Lung Analysis Platform that is used for clinical assessment and cloud-based CT analysis.

Profitability and growth are driven by adoption at pulmonary treatment centers, reflected in operating metrics like active revenue-generating accounts and active Zephyr Valve accounts, which determine how much of the valve and related assessment workflow gets used and scaled over time.

Revenue by segment (latest quarter)
US$0.0B
Intl$0.0B

Business quality (Weak): Trackable center-based adoption metrics exist, but the latest quarter shows a very weak operating margin, so investors typically need to see evidence of sustained account productivity and scale before expecting improved profitability.

Bull case

  • Zephyr adoption appears to be managed through a network of treatment centers, with active revenue-generating centers and active Zephyr Valve accounts provided as operating metrics: In the latest quarter, active revenue-generating centers and active Zephyr Valve accounts both exist at substantial levels, supporting the idea that the company is working to build an installed base for its products and workflows.
  • Access and targeting through payer and coverage metrics are tracked: The company reports Blue Cross Blue Shield covered lives with Zephyr Valve access and commercially covered lives with Zephyr Valve access, suggesting commercialization efforts tied to reimbursement access.

Bear case

  • Profitability is currently very weak: Operating margin is negative in the latest reported period (operating margin pct is -62.9), which increases the risk that growth may not translate into sustainable operating profits.
  • Revenue exposure is split between the United States and International: The provided segment revenue breakdown shows both US and International, so investors would need to monitor whether adoption and monetization are improving consistently across both geographies.
Valuation — source: SEC EDGAR (first-party)
Price$2.31
Market Cap$97.57M
Price / Book2.13
Price / Sales1.10
FCF Yield-68.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$90.50M
Net Margin-59.7%
Revenue Growth (YoY)8.0%
EPS Growth (YoY)-7.6%
FCF Growth (YoY)-0.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-4.78 (distress)
Piotroski F-Score3/9 (weak)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderPRIMECAP MANAGEMENT CO/CA/ ($6.10M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOGlendon E. French
Employees291
CountryUS
IPO Date2020-10-01

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Lucid Diagnostics Inc. (LUCD)
  • Femasys Inc. (FEMY)
  • KORU Medical Systems, Inc. (KRMD)
  • Apyx Medical Corporation (APYX)
  • Microbot Medical Inc. (MBOT)
  • Sharps Technology, Inc. (STSS)
  • CVRx, Inc. (CVRX)
  • DarioHealth Corp. (DRIO)
LUNG earnings history · LUNG institutional & insider holders · LUNG KPIs & operating metrics · LUNG financials · LUNG investor presentations & press releases · LUNG SEC filings · LUNG peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.